Supplementary Table 2. Rating of individual items of the Risk of Bias tool for each study.

## Note: CSR: Clinical Study Report

ACTIV-3/TICO LY-CoV555 Study Group [18]

	3 010up [10]	
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Notes	First author cont	tacted but not able to provide additional information.
Ahmed S et al [19]	-	
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.
Notes	Authors contact	ed but no reply.
Aman J et al [20]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.

Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.
Notes	First author contac	cted but not able to provide additional information.
Biber A et al [21]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.
Notes	Authors contacted	but no reply.
Blum Vf et al [22]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	UNCLEAR	No details on incomplete data outcome.
Selective reporting	LOW	Outcomes listed in the CSR synopsis reported in the journal article.
Other bias	UNCLEAR	No details on other bias.
Notes	Not possible to co	ntact authors.
Cadegiani FA et al (a) [23]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.

Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	LOW	First author confirmed that all measures listed in the protocol are reported in the journal article.	
Other bias	<b>UNCLEAR</b>	No details on other bias.	
Notes	First author provi	ded additional information.	
Cadegiani FA et al (b) [24]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	<b>UNCLEAR</b>	No details on selective reporting.	
Other bias	UNCLEAR	No details on other bias.	
Notes	First author infor	med that additional data are not available anymore.	
Caricchio R et al [25]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	UNCLEAR	No details on selective reporting.	
Other bias	<b>UNCLEAR</b>	No details on other bias.	
Notes	First author conta	First author contacted but not able to provide additional information.	

Chaccour C et al [26]

	DATING		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from the Journal article, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	UNCLEAR	No protocol/CSR available.	
Blinding assessor	UNCLEAR	No protocol/CSR available.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned were reported in the Journal article.	
Selective reporting	LOW	Information provided by the manufacturer: some outcomes were not reported in the journal article (however, available	
		from Clinicaltrials.gov.)	
Other bias	<b>UNCLEAR</b>	No protocol/CSR available.	
Notes	Manufacturer prov	vided additional information.	
Chen J et al [27]	-		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from the Journal article, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	UNCLEAR	No protocol/CSR available.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were	
		supplied." Information from the Journal article, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned were reported in the Journal article.	
Selective reporting	UNCLEAR	No protocol/CSR available.	
Other bias	UNCLEAR	No protocol/CSR available.	
Notes	First author contact	cted but not able to provide additional information.	
Devpura G et al [28]	Devpura G et al [28]		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were	
binding participants/personner		supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were	
		supplied." Information from full CSR, Blinding.	
Incomplete data outcome	UNCLEAR	No details on incomplete data outcome.	
Selective reporting	LOW	Information provided by the manufacturer: some outcomes were not reported in the journal article (however, available	
	UNCLEAR	from Clinicaltrials.gov.) No details on other bias.	
Other bias			
Notes	Authors provided additional information.		

Dubee V et al [29]

ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
		"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were	
Blinding participants/personnel	LOW	supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	LOW	Information provided by the manufacturer: some outcomes were not reported in the journal article (however, available from Clinicaltrials.gov.)	
Other bias	UNCLEAR	No details on other bias.	
Notes	Authors provided	additional information.	
Eom JS et al [30]	Eom JS et al [30]		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	UNCLEAR	No details on selective reporting.	
Other bias	UNCLEAR	No details on other bias.	
Notes	First author contact	cted but not able to provide additional information.	
Feld JJ et al [31]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	

Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	Primary and secondary outcomes listed in full CSR all reported in the journal article.
Other bias	UNCLEAR	No details on other bias.
Notes		additional information.
Gonzalez-Ochoa AG et al [32]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information fromhe Journal article, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	HIGH	No information on how blinding was preserved.
Blinding assessor	HIGH	No information on how blinding was preserved.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned were reported in the Journal article.
Selective reporting	<b>UNCLEAR</b>	No protocol/CSR available.
Other bias	<b>UNCLEAR</b>	No protocol/CSR available.
Notes	First author conta	acted but not able to provide additional information.
Gottlieb RL et al [33]	•	
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	Manufacturer confirmed that "All outcomes were reported in published papers".
Other bias	<b>UNCLEAR</b>	No details on other bias.
Notes	Authors provided	additional information.
Gunst GD et al [34]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.

Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	LOW	Manufacturer confirmed that "All outcomes were reported in published papers".	
Other bias	UNCLEAR	No details on other bias.	
Notes	Authors provided	additional information.	
Gupta A et al [35]	Gupta A et al [35]		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	LOW	Outcomes relevant for the present meta-analysis mentioned in the CSR were reported in the Journal article.	
Other bias	UNCLEAR	No details on other bias.	
Notes	First author provided additional information.		

## Gutierrez-Castrellon P et al [36]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.
Notes	Author contacted but no reply.	
Humeniuk R et al [37]		
ITEM	RATING	SUPPORT

Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.
Notes	Author contacted	but no reply.
Jagannathan P et al [38]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from the Journal article, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	UNCLEAR	No protocol/CSR available.
Blinding assessor	UNCLEAR	No protocol/CSR available.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned were reported in the Journal article.
Selective reporting	UNCLEAR	No protocol/CSR available.
Other bias	UNCLEAR	No protocol/CSR available.
Notes	First author conta	cted but not able to provide additional information.
Jeronimo CMP et al [39]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	<b>UNCLEAR</b>	No details on incomplete data outcome.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.
Notes	Author contacted	but no reply.
Lenze EJ et al [40]		
ITEM	RATING	SUPPORT

Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	<b>UNCLEAR</b>	No details on other bias.
Notes	Corresponding au	thor contacted but not able to provide additional information.
López-Medina E et al [41]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	UNCLEAR	No details on incomplete data outcome.
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	<b>UNCLEAR</b>	No details on other bias.
Notes	First author provi	ded additional information.
Marconi VC et al [42]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	Outcomes pertinent to the present meta-analysis identified in the full CSR reported.
Other bias	UNCLEAR	No details on other bias.

tes Corresponding author contacted but no reply.			
Notes	conceponante autor contacted cat no repry.		
McCoy J et al [43] ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	UNCLEAR	No details on incomplete data outcome.	
Selective reporting	UNCLEAR	No details on selective reporting.	
Other bias	UNCLEAR	No details on other bias.	
Notes	First author provid	led additional information.	
Mohan A et al [44]	Mohan A et al [44]		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	UNCLEAR	No details on incomplete data outcome.	
Selective reporting	<b>UNCLEAR</b>	No details on selective reporting.	
Other bias	UNCLEAR	No details on other bias.	
Notes	First author contac	ted but not able to provide additional information.	
Monk PD et al [45]	-		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	

Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.
Notes		cted but not able to provide additional information.
Omrani AS et al [46]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full article, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	HIGH	No details on who was blinded and how blinding was preserved.
Blinding assessor	UNCLEAR	No protocol/CSR available.
Incomplete data outcome	UNCLEAR	No protocol/CSR available.
Selective reporting	UNCLEAR	No protocol/CSR available.
Other bias	HIGH	No protocol/CSR available.
Notes	Corresponding au	thor not able to provide additional details.
Patel O et al [47]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	All outcomes of relevance reported in published journal article.
Other bias	UNCLEAR	Not specified.
Notes	First author provid	ded additional information.
Puskarich MA et al [48]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.

Selective reporting	LOW	All outcomes of relevance reported in published journal article.	
Other bias	UNCLEAR	Not specified.	
Notes	First author contac	ted but not able to provide additional information.	
Rastogi A et al [49]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from journal article, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	UNCLEAR	No protocol/CSR available.	
Blinding assessor	UNCLEAR	No protocol/CSR available.	
Incomplete data outcome	UNCLEAR	No protocol/CSR available.	
Selective reporting	LOW	All outcomes of relevance reported in published journal article.	
Other bias	UNCLEAR	No protocol/CSR available.	
Notes	First author unable to provide additional details.		
Ravikirti et al [50]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full article, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	UNCLEAR	No protocol/CSR available.	
Blinding assessor	UNCLEAR	No protocol/CSR available.	
Incomplete data outcome	UNCLEAR	No protocol/CSR available.	
Selective reporting	LOW	All outcomes of relevance reported in published journal article.	
Other bias	UNCLEAR	No protocol/CSR available.	
Notes	First author contac	ted but not able to provide additional information.	
Reis G et al [51]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	HIGH	No details on who was blinded and how blinding was preserved.	
Blinding assessor	HIGH	No details on who was blinded and how blinding was preserved.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	UNCLEAR	Not specified.	
Other bias	LOW	All reported in published papers.	

Notes	First author unable to provide additional details.		
Rocco PRM et al [52]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from the full article, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from the full article, Blinding.	
Blinding assessor	UNCLEAR	No protocol/CSR available.	
Incomplete data outcome	UNCLEAR	No protocol/CSR available.	
Selective reporting	LOW	All outcomes of relevance reported in published journal article.	
Other bias	LOW	All reported in published papers.	
Notes	First author unable	e to provide additional details.	
Salama C et al [53]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from the full article, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from the full article, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from the full article, Blinding.	
Incomplete data outcome	UNCLEAR	No protocol/CSR available.	
Selective reporting	UNCLEAR	No protocol/CSR available.	
Other bias	UNCLEAR	No protocol/CSR available.	
Notes	First author unable	e to provide additional details.	
Silva M et al [54]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from the full article, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from the full article, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from the full article, Blinding.	
Incomplete data outcome	UNCLEAR	No protocol/CSR available.	
Selective reporting	UNCLEAR	No protocol/CSR available.	
Other bias	UNCLEAR	No protocol/CSR available.	

Notes	First author contacted but not able to provide additional information.		
Sivapalan P et al [55]			
ITEM	RATING	SUPPORT	
	LOW	Received medications and placebo in a random order, double-blind.	
Random sequence generation			
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	UNCLEAR	Not specified.	
Selective reporting	HIGH	Unbalanced reasons for selective reporting.	
Other bias	LOW	No protocol/CSR available.	
Notes	First author contac	ted but not able to provide additional information.	
Skipper CP et al [56]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	UNCLEAR	Not specified.	
Other bias	LOW	All information listed in clinialtrial.gov was reported in the journal article.	
Notes	Authors provided	additional information.	
Stone JH et al [57]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	UNCLEAR	Not specified.	

	LOW		
Selective reporting		All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)	
Other bias	UNCLEAR	Not specified.	
Notes	Authors provided	d additional information.	
Tardif JC et al [58]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	LOW	All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)	
Other bias	<b>UNCLEAR</b>	Not specified.	
Notes	Authors provided	d additional information.	
Tornling G et al [59]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding participants/personnel Blinding assessor	LOW <mark>UNCLEAR</mark>		
		supplied." Information from full CSR, Blinding.	
Blinding assessor	UNCLEAR	supplied." Information from full CSR, Blinding. Not specified.	
Blinding assessor Incomplete data outcome	UNCLEAR LOW	supplied." Information from full CSR, Blinding.         Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Blinding assessor Incomplete data outcome Selective reporting	UNCLEAR LOW UNCLEAR LOW	supplied." Information from full CSR, Blinding.         Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.	
Blinding assessor Incomplete data outcome Selective reporting Other bias	UNCLEAR LOW UNCLEAR LOW	supplied." Information from full CSR, Blinding.         Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         All information listed in clinialtrial.gov was reported in the journal article.	
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes	UNCLEAR LOW UNCLEAR LOW	supplied." Information from full CSR, Blinding.         Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         All information listed in clinialtrial.gov was reported in the journal article.	
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes Ulrich RJ et al [60]	UNCLEAR LOW UNCLEAR LOW First author conta	supplied." Information from full CSR, Blinding.         Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         All information listed in clinialtrial.gov was reported in the journal article.         acted but not able to provide additional information.	
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes Ulrich RJ et al [60] ITEM	<ul> <li>UNCLEAR</li> <li>LOW</li> <li>UNCLEAR</li> <li>EOW</li> <li>First author contains</li> </ul>	supplied." Information from full CSR, Blinding.         Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         All information listed in clinialtrial.gov was reported in the journal article.         acted but not able to provide additional information.         SUPPORT	

	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to
Blinding assessor	LOW	maintain double-blind conditions.
Incomplete data outcome	<b>UNCLEAR</b>	Not specified.
Selective reporting	LOW	All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)
Other bias	<b>UNCLEAR</b>	Not specified.
Notes	Authors provided	d additional information.
Vallejos J et al [61]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to maintain double-blind conditions.
Incomplete data outcome	<b>UNCLEAR</b>	Not specified.
Selective reporting	<b>UNCLEAR</b>	Not specified.
Other bias	LOW	All information listed in clinialtrial.gov was reported in the journal article.
Notes	Authors provide	d additional information.
Wang Y et al [62]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to maintain double-blind conditions.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)
Other bias	UNCLEAR	Not specified.
Notes	First author cont	acted but not able to provide additional information.
Weinreich DM et al [63]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.

Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to
munig assessor		maintain double-blind conditions.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	Not specified.
Other bias	<b>UNCLEAR</b>	Not specified.
Notes	Authors not abl	le to provide additional information.
CaoY et al [64]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	HIGH	No details on who was blinded and how blinding was preserved.
Blinding assessor	HIGH	No details on who was blinded and how blinding was preserved.
Incomplete data outcome	<b>UNCLEAR</b>	Not specified.
Selective reporting	LOW	All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)
Other bias	<b>UNCLEAR</b>	Not specified.
Notes	First author cor	ntacted but not able to provide additional information.
Cremer PC et al [65]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	<b>UNCLEAR</b>	Not specified.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to maintain double-blind conditions.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)
Other bias	<b>UNCLEAR</b>	Not specified.
Notes	Authors not abl	le to provide additional information.
de Alencar JCG et al [66]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .

Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were
binding participants/personner		supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to
		maintain double-blind conditions.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	Not specified.
Other bias	<b>UNCLEAR</b>	Not specified.
Notes	First author conta	teted but not able to provide additional information.
Dequin PF et al [67]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Dlinding posticinents/personnal	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to
Blinding participants/personnel	LOW	maintain double-blind conditions.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were
		supplied." Information from full CSR, Blinding.
Incomplete data outcome	<b>UNCLEAR</b>	Not specified.
Selective reporting	<b>UNCLEAR</b>	Not specified.
Other bias	<b>UNCLEAR</b>	Not specified.
Notes	Manufacturer pro	vided additional information.
Gharebaghi N et al [68]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Dlin din a norti sin onta/norrownal	LOW	Throughout, a pharmacy prepared, distributed and tracked all the drugs, separately from raters and subjects in order to
Blinding participants/personnel	LOW	maintain double-blind conditions.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were
		supplied." Information from full CSR, Blinding.
Incomplete data outcome	<b>UNCLEAR</b>	Not specified.
Selective reporting	LOW	All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)
Other bias	<b>UNCLEAR</b>	Not specified.
Notes	First author conta	icted but not able to provide additional information.
Lagouro EV of al [60]		

Lescure FX et al [69]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	All outcomes listed in clinialtrial.gov were reported in the journal article (which included additional outcomes)
Other bias	UNCLEAR	Not specified.
Notes	Authors not able t	o provide additional information.
Libster R et al [70]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	Not specified.
Other bias	UNCLEAR	Not specified.
Notes	Contacted author	but not valid e-mail; no other e-mail addresses found.
Munch MW et al [71]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	Not specified.

Other bias	LOW	All information listed in clinialtrial.gov was reported in the journal article.		
Notes	Contacted author but not valid e-mail; no other e-mail addresses found.			
Rosas IO et al [72]				
ITEM	RATING	SUPPORT		
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.		
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.		
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.		
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.		
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.		
Selective reporting	LOW	Outcomes listed in short CSR reported in the journal article.		
Other bias	UNCLEAR	Not specified.		
Notes	E-mail address for	E-mail address for corresponding author not valid; no other email addresses found.		
Sehgal IS et al [73]				
ITEM	RATING	SUPPORT		
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.		
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.		
		"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were		
Blinding participants/personnel	LOW	supplied." Information from full CSR, Blinding.		
Blinding participants/personnel Blinding assessor	LOW <mark>UNCLEAR</mark>	supplied." Information from full CSR, Blinding. Not specified.		
Blinding assessor	UNCLEAR	Not specified.		
Blinding assessor Incomplete data outcome	UNCLEAR LOW	Not specified. Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.		
Blinding assessor Incomplete data outcome Selective reporting	UNCLEAR LOW UNCLEAR UNCLEAR	Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.		
Blinding assessor Incomplete data outcome Selective reporting Other bias	UNCLEAR LOW UNCLEAR UNCLEAR	Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         Not specified.		
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes Shi L et al [74]	UNCLEAR LOW UNCLEAR UNCLEAR	Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         Not specified.		
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes Shi L et al [74] ITEM	UNCLEAR LOW UNCLEAR UNCLEAR First author contac	Not specified. Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article. Not specified. Not specified. eted but not able to provide additional information.		
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes Shi L et al [74]	UNCLEAR LOW UNCLEAR UNCLEAR First author contact	Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         Not specified.         eted but not able to provide additional information.		
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes Shi L et al [74] ITEM Random sequence generation	UNCLEAR LOW UNCLEAR UNCLEAR First author contact	Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         Not specified.         ted but not able to provide additional information.         SUPPORT         Received medications and placebo in a random order, double-blind .		
Blinding assessor Incomplete data outcome Selective reporting Other bias Notes Shi L et al [74] ITEM Random sequence generation Allocation concealment	UNCLEAR LOW UNCLEAR UNCLEAR First author contact RATING LOW LOW	Not specified.         Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.         Not specified.         Not specified.         eted but not able to provide additional information.         SUPPORT         Received medications and placebo in a random order, double-blind .         Information from full CSR, Method of Assigning Subjects to Treatment Groups.         "Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were		

Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	LOW	Outcomes listed in short CSR reported in the journal article.	
Other bias	UNCLEAR	Not specified.	
Notes		ovided additional information.	
Simonovich VA et al [75]			
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	<b>UNCLEAR</b>	Not specified.	
Blinding assessor	<b>UNCLEAR</b>	Not specified.	
Incomplete data outcome	UNCLEAR	Not specified.	
Selective reporting	LOW	Outcomes listed in short CSR reported in the journal article.	
Other bias	<b>UNCLEAR</b>	Not specified.	
Notes	First author cont	tacted but not able to provide additional information.	
Sivapalasingam S et al [76]	-		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.	
Selective reporting	UNCLEAR	Not specified.	
Other bias	<b>UNCLEAR</b>	Not specified.	
Notes	Authors not able	e to provide additional information.	
Temesgen Z et al [77]	-		
ITEM	RATING	SUPPORT	
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind .	
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.	
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.	

Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	UNCLEAR	Not specified.
Other bias	UNCLEAR	Not specified.
Notes	First author contac	eted but not able to provide additional information.
Zhong M et al [78]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	UNCLEAR	Not specified.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal article.
Selective reporting	LOW	Outcomes listed in short CSR reported in the journal article.
Other bias	UNCLEAR	Not specified.
Notes	Authors not able to provide additional information.	